Embecta

Embecta Gross Profit/Assets

The Gross Profit to Assets Ratio of Embecta (EMBC) as of Oct 22, 2026 is 62.29 %. In the previous year, Gross Profit to Assets Ratio was 56.71 % — a change of 9.84% (higher).

Gross Profit/Assets

62.29 %

YoY

9.84%

Last updated:

Gross Profit to Assets Ratio of Embecta is 2025 62.29 % . Gross Profit to Assets Ratio of Embecta was 2024 56.71 % . It decreases by 9.84% higher compared to the previous year.

The Embecta Gross Profit/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit/Assets
Date
Gross Profit/Assets
Jan 1, 2019
105.50 USD
Jan 1, 2020
103.39 USD
Jan 1, 2021
101.52 USD
Jan 1, 2022
71.33 USD
Jan 1, 2023
61.75 USD
Jan 1, 2024
56.71 USD
Jan 1, 2025
62.29 USD
The Embecta Gross Profit/Assets history
YEARGross Profit/AssetsYoY
62.29 %+9.84%
56.71 %-8.16%
61.75 %-13.43%
71.33 %-29.74%
101.52 %-1.80%
103.39 %-2.01%
105.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta Stock analysis

What does Embecta do? Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management. Embecta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Embecta stock

Gross Profit to Assets Ratio of Embecta is 62.29 % in 2025.

Gross Profit to Assets Ratio of Embecta changed from 56.71 % to 62.29 %, representing a 9.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit to Assets Ratio Embecta since 2006 – with annual values, charts, and detailed analysis.

Gross Profit/Assets measures how efficiently a company uses its assets to generate gross profit. Research shows it is a strong predictor of future stock returns.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Profit to Assets Ratio's Embecta with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Profit to Assets Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Profit to Assets Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Embecta

All Key Metrics — Embecta